AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOGEN INC. Director's Dealing 2012

Jan 4, 2012

30291_dirs_2012-01-04_8f413128-bdf4-4085-9d23-eda1471b3673.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN IDEC INC. (BIIB)
CIK: 0000875045
Period of Report: 2012-01-03

Reporting Person: Clancy Paul J (Executive VP and CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-01-03	Common Stock	S	14670	$112.2193	Disposed	26742	Direct
2012-01-03	Common Stock	S	5574	$112.6918	Disposed	21168	Direct

Footnotes

F1: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2: Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or a security holder of the issuer.

F3: This represents the weighted average price for shares sold at a range between $111.45 (low) and $112.44 (high).

F4: This represents the weighted average price for shares sold at a range between $112.45 (low) and $112.94 (high).